Xencor Reports Third Quarter 2026 Financial Results
Xencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.